Skip to main content
Top
Published in: Tumor Biology 10/2014

01-10-2014 | Research Article

Association between TNF-α gene 308G>A polymorphism and lung cancer risk: a meta-analysis

Authors: Haojun Xie, Hongmei Yao, Yating Huo, Ning Li, Yuanxiong Cheng

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

Many studies have investigated the association between tumor necrosis factor alpha (TNF-α) gene 308G/A polymorphism and lung cancer risk, but the results were inconsistent. We thus comprehensively searched the PubMed, EMBASE, and BIOSIS Previews databases and extracted data from all eligible articles to estimate the association between TNF-α gene 308G/A polymorphism and lung cancer risk. The pooled odds ratio (OR) with 95 % confidence intervals (CIs) were calculated. Twelve case–control studies in 11 articles involving 2,436 cases and 2,573 controls were included in the meta-analysis to assess the association between TNF-α gene 308G>A polymorphism and susceptibility to lung cancer. Overall, TNF-α gene 308G>A polymorphism was significantly associated with an increased risk of lung cancer for A vs. G (OR = 1.13, 95 % CI 1.00 ~ 1.27, P = 0.04). Subgroup analysis by ethnicity showed that there was a significant association between TNF-α gene 308G>A polymorphism and increased risk of lung cancer in Asians, but not in Caucasians. In subgroup analysis by tumor type, there were significant associations between TNF-α gene 308G>A polymorphism and increased risk of lung cancer in small cell lung cancer (SCLC) for AA+AG vs. GG, in non-small cell lung cancer (NSCLC) for A vs. G, AA vs. GG, and AA+AG vs. GG. No association between the genotypes and different stages of lung cancer was detected. The meta-analysis suggests that TNF-α gene 308G>A polymorphism is associated with an increased risk of lung cancer, particularly among Asians, both for SCLC and NSCLC, considering tumor type.
Literature
2.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMed
3.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
4.
go back to reference Ozlu T, Bulbul Y. Smoking and lung cancer. Tuberk Toraks. 2005;53:200–9.PubMed Ozlu T, Bulbul Y. Smoking and lung cancer. Tuberk Toraks. 2005;53:200–9.PubMed
6.
go back to reference Sellers TA, Bailey-Wilson JE, Elston RC, Wilson AF, Elston GZ, Ooi WL, et al. Evidence for Mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst. 1990;82:1272–9.CrossRefPubMed Sellers TA, Bailey-Wilson JE, Elston RC, Wilson AF, Elston GZ, Ooi WL, et al. Evidence for Mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst. 1990;82:1272–9.CrossRefPubMed
7.
go back to reference Sellers TA, Chen PL, Potter JD, Bailey-Wilson JE, Rothschild H, Elston RC. Segregation analysis of smoking-associated malignancies: evidence for Mendelian inheritance. Am J Med Genet. 1994;52:308–14.CrossRefPubMed Sellers TA, Chen PL, Potter JD, Bailey-Wilson JE, Rothschild H, Elston RC. Segregation analysis of smoking-associated malignancies: evidence for Mendelian inheritance. Am J Med Genet. 1994;52:308–14.CrossRefPubMed
9.
go back to reference Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V, Milevoj-Ribic F. Cytokines in patients with lung cancer. Scand J Immunol. 2003;57:173–8.CrossRefPubMed Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V, Milevoj-Ribic F. Cytokines in patients with lung cancer. Scand J Immunol. 2003;57:173–8.CrossRefPubMed
10.
go back to reference Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001;98:9824–9.PubMedCentralCrossRefPubMed Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001;98:9824–9.PubMedCentralCrossRefPubMed
11.
go back to reference McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004;91:1993–5.PubMedCentralCrossRefPubMed McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004;91:1993–5.PubMedCentralCrossRefPubMed
12.
go back to reference Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565–73.CrossRefPubMed Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565–73.CrossRefPubMed
13.
14.
go back to reference Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:947–52.CrossRefPubMed Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:947–52.CrossRefPubMed
15.
go back to reference Shen C, Sun H, Sun D, Xu L, Zhang X, Liu A, et al. Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011;126:763–70.CrossRefPubMed Shen C, Sun H, Sun D, Xu L, Zhang X, Liu A, et al. Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011;126:763–70.CrossRefPubMed
16.
go back to reference Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, et al. Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. J Hum Genet. 2008;53:479–89.CrossRefPubMed Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, et al. Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. J Hum Genet. 2008;53:479–89.CrossRefPubMed
17.
go back to reference Colakogullari M, Ulukaya E, Oral AY, Aymak F, Basturk B, Ursavas A, et al. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct. 2008;26:283–90.CrossRefPubMed Colakogullari M, Ulukaya E, Oral AY, Aymak F, Basturk B, Ursavas A, et al. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct. 2008;26:283–90.CrossRefPubMed
18.
go back to reference Flego V, Badovinac AR, Bulat-Kardum L, Matanic D, Crnic-Martinovic M, Kapovic M, et al. Primary lung cancer and TNF-(alpha) gene polymorphisms: a case-control study in a Croatian population. Med Sci Monit. 2009;15:R361–5. Flego V, Badovinac AR, Bulat-Kardum L, Matanic D, Crnic-Martinovic M, Kapovic M, et al. Primary lung cancer and TNF-(alpha) gene polymorphisms: a case-control study in a Croatian population. Med Sci Monit. 2009;15:R361–5.
19.
go back to reference Flego V, Ristic S, Devic Pavlic S, Matanic Lender D, Bulat-Kardum L, Kapovic M, et al. Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor. Med Sci Monit. 2013;19:846–51.PubMedCentralCrossRefPubMed Flego V, Ristic S, Devic Pavlic S, Matanic Lender D, Bulat-Kardum L, Kapovic M, et al. Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor. Med Sci Monit. 2013;19:846–51.PubMedCentralCrossRefPubMed
20.
go back to reference Helmig S, Aliahmadi N, Schneider J. Tumour necrosis factor-alpha gene polymorphisms in asbestos-induced diseases. Biomarkers. 2010;15:400–9.CrossRefPubMed Helmig S, Aliahmadi N, Schneider J. Tumour necrosis factor-alpha gene polymorphisms in asbestos-induced diseases. Biomarkers. 2010;15:400–9.CrossRefPubMed
21.
go back to reference Huang Y. BYLM: TNF-alpha gene polymorphism in patients with lung squamous carcinoma. Natl Med J China. 2005;15:1064–5. Huang Y. BYLM: TNF-alpha gene polymorphism in patients with lung squamous carcinoma. Natl Med J China. 2005;15:1064–5.
22.
go back to reference Kaabachi S, Kaabachi W, Rafrafi A, Belkis H, Hamzaoui K, Sassi FH. Tumor necrosis factor gene polymorphisms in Tunisian patients with non-small cell lung cancer. Clin Lab. 2013;59:1389–95.PubMed Kaabachi S, Kaabachi W, Rafrafi A, Belkis H, Hamzaoui K, Sassi FH. Tumor necrosis factor gene polymorphisms in Tunisian patients with non-small cell lung cancer. Clin Lab. 2013;59:1389–95.PubMed
23.
24.
go back to reference Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, et al. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers. 2005;21:157–65.PubMedCentralCrossRefPubMed Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, et al. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers. 2005;21:157–65.PubMedCentralCrossRefPubMed
25.
go back to reference Shih C, Lee Y. Role of tumour necrosis factor alpha-gene polymorphisms (-238 and -308) in non-small cell lung cancer susceptibility and severity. Lung Cancer-J IASLC. 2005;49:S145.CrossRef Shih C, Lee Y. Role of tumour necrosis factor alpha-gene polymorphisms (-238 and -308) in non-small cell lung cancer susceptibility and severity. Lung Cancer-J IASLC. 2005;49:S145.CrossRef
26.
go back to reference Stankovic MM, Nestorovic AR, Tomovic AM, Petrovic-Stanojevic ND, Andjelic-Jelic MS, Dopudja-Pantic VB, et al. TNF-(alpha)-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. Neoplasma. 2009;56:348–52.CrossRefPubMed Stankovic MM, Nestorovic AR, Tomovic AM, Petrovic-Stanojevic ND, Andjelic-Jelic MS, Dopudja-Pantic VB, et al. TNF-(alpha)-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. Neoplasma. 2009;56:348–52.CrossRefPubMed
27.
go back to reference Van Dyke AL, Cote ML, Wenzlaff AS, Chen W, Abrams J, Land S, et al. Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev. 2009;18:1829–40.PubMedCentralCrossRefPubMed Van Dyke AL, Cote ML, Wenzlaff AS, Chen W, Abrams J, Land S, et al. Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev. 2009;18:1829–40.PubMedCentralCrossRefPubMed
28.
go back to reference Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, et al. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep. 2012;39:5187–94.CrossRefPubMed Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, et al. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep. 2012;39:5187–94.CrossRefPubMed
29.
go back to reference Wang J, Cao C, Luo H, Xiong S, Xu Y, Xiong W. Tumour necrosis factor alpha -308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet. 2011;38:311–20.CrossRefPubMed Wang J, Cao C, Luo H, Xiong S, Xu Y, Xiong W. Tumour necrosis factor alpha -308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet. 2011;38:311–20.CrossRefPubMed
30.
go back to reference Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.CrossRefPubMed Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.CrossRefPubMed
31.
go back to reference Huang G, Cai S, Wang W, Zhang Q, Liu A. Association between XRCC1 and XRCC3 polymorphisms with lung cancer risk: a meta-analysis from case-control studies. PLoS One. 2013;8:e68457.PubMedCentralCrossRefPubMed Huang G, Cai S, Wang W, Zhang Q, Liu A. Association between XRCC1 and XRCC3 polymorphisms with lung cancer risk: a meta-analysis from case-control studies. PLoS One. 2013;8:e68457.PubMedCentralCrossRefPubMed
32.
go back to reference Huang SX, Wu FX, Luo M, Ma L, Gao KF, Li J, et al. The glutathione S-transferase P1 341C>T polymorphism and cancer risk: a meta-analysis of 28 case-control studies. PLoS One. 2013;8:e56722.PubMedCentralCrossRefPubMed Huang SX, Wu FX, Luo M, Ma L, Gao KF, Li J, et al. The glutathione S-transferase P1 341C>T polymorphism and cancer risk: a meta-analysis of 28 case-control studies. PLoS One. 2013;8:e56722.PubMedCentralCrossRefPubMed
33.
go back to reference Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312:724–9.CrossRefPubMed Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312:724–9.CrossRefPubMed
34.
go back to reference Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988;167:1211–27.CrossRefPubMed Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988;167:1211–27.CrossRefPubMed
35.
36.
go back to reference Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–9.CrossRefPubMed Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–9.CrossRefPubMed
Metadata
Title
Association between TNF-α gene 308G>A polymorphism and lung cancer risk: a meta-analysis
Authors
Haojun Xie
Hongmei Yao
Yating Huo
Ning Li
Yuanxiong Cheng
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2265-6

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine